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Objective: Empirical results indicate an increased risk for cardiovascular (CV) adverse drug
events (ADE) in chronic obstructive pulmonary disease (COPD) patients treated with beta-2-
agonists (B2A) and muscarinic antagonists (MA). A systematic review (including a meta-
analysis for drug classes with sufficient sample size) was conducted assessing the association
between B2A or MA and acute myocardial infarctions (MI) in COPD patients.2180 72406; fax: þ49 89 2180 72404.
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1076 M. Rottenkolber et al.Acute myocardial
infarction;
Systematic review;
Chronic obstructive
pulmonary diseaseMethods: Comprehensive literature search in electronic databases (MEDLINE, Cochrane data-
base) was performed (January 1, 1946eApril 1, 2013). Results were presented by narrative syn-
thesis including a comprehensive quality assessment. In the meta-analysis, a random effects
model was used for estimating relative risk estimates for acute MI.
Results: Eight studies (two systematic reviews, two randomized controlled trials, and four
observational studies) were comprised. Most studies comparing tiotropium vs. placebo showed
a decreased MI risk for tiotropium, whereas for studies with active control arms no clear ten-
dency was revealed. For short-acting B2A, an increased MI risk was shown after first treatment
initiation. For all studies, a good quality was found despite some shortcomings in ADE-specific
criteria. A meta-analysis could be conducted for tiotropium vs. placebo only, showing a rela-
tive risk reduction of MI (0.74 [0.61e0.90]) with no evidence of statistical heterogeneity among
the included trials (I2 Z 0%; p Z 0.8090).
Conclusions: An MI-protective effect of tiotropium compared to placebo was found, which
might be attributable to an effective COPD treatment leading to a decrease in COPD-related
cardiovascular events. Further studies with effective control arms and minimal CV risk are
required determining precisely tiotropium’s cardiovascular risk.
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Chronic obstructive pulmonary disease (COPD) is one of the
most common chronic airway diseases in Western countries.
A stepwise treatment using several drug classes is recom-
mended to reduce symptoms, improve lung function, and
prevent risk of exacerbation. According to current guide-
lines (e.g., Global Initiative for Chronic Obstructive Lung
Disease [GOLD]) [1], beta-2-adrenoceptor agonists (B2A)
are therapeutic mainstays of COPD treatment because oftheir bronchodilative effects. This drug class consists of two
types: short-acting B2A (SABA) prescribed as reliever
medication and long-acting B2A (LABA) used as mainte-
nance/control medication. Widely taken SABA products
with a short half-life are salbutamol, fenoterol, and ter-
butalin. Formoterol and salmeterol are the most frequently
used LABA products that have a recommended twice-daily
usage.
A second bronchodilative drug class that acts on the
cholinergic system (muscarinic antagonists [MA]) is also
Respiratory drug-related myocardial infarction 1077recommended to treat COPD. Similarly to B2A, these MA
drugs can be classified in short-acting MA (SAMA) and long-
acting MA (LAMA) according to their half-life period.
Currently available products in these classes are ipra-
tropium (SAMA) and tiotropium or oxitropium (LAMA).
Focussing on adverse drug events (ADE) of B2A, stimu-
lation of cardiac beta-adrenoceptors by B2A and anticho-
linergic effects by MA have been related to cardiovascular
ADE, particularly in patients exhibiting cardiac risk factors
[2]. For example, tachycardia and arrhythmias are well-
known side effects for both drug classes [2,3].
Both randomised controlled trials and observational
studies have been performed to assess the association be-
tween the usage of inhaled B2A and the occurrence of MI
[4e6] resulting in conflicting evidence. Potential reasons
for these differences may be misclassification of potential
cardiac vs. airway-related events due to similar clinical
complaints, differing baseline risk of MI in B2A users and
non-users, different measurement of drug exposure, and aFigure 1 Literature search (flow chartsmall number of events resulting in poor precision of risk
estimates.
To contribute on this area of research, we performed an
independent systematic review to assess the association
between B2A or MA and MI (fatal and non-fatal) in COPD
populations. In addition, after finishing the narrative syn-
thesis, a meta-analysis was conducted for those drug clas-
ses the sample sizes were sufficient.Methods
Literature search
In a first step, in order to analyze the current status of
research, both meta-analyses and existing systematic re-
views dealing with the association between B2A or MA and
MI were searched for in different databases (Fig. 1). Hence,
a comprehensive computer-based literature search using a, RCT: Randomised controlled trial).
1078 M. Rottenkolber et al.predefined set of keywords was conducted in electronic
databases (MEDLINE, Cochrane database) aiming to identify
manuscripts dealing with the drugeadverse effect pair
“B2A” or “MA” and “acute myocardial infarction”. The full
search term expression is presented in Appendix 1. Acute
myocardial infarctions caused by B2A or MA are very rare
adverse events (AE). Therefore, the term “acute myocar-
dial infarction” is not expected to be contained in neither
the publications’ abstracts nor keyword lists. Hence, to
deal with this problem and to retrieve all relevant publi-
cations, the search terms for the adverse event remained
very unspecific to achieve an optimal coverage. All stages
of publications (early view, in press, or published) were
considered relevant for publication. Only English language
articles were considered relevant in further analysis. Re-
sults were limited to the years January 1, 1946eApril 1,
2013. Further publications were found by bibliographic
hand search in key articles, key journals, and by citation
tracking.
In a second step, the most recent high-quality system-
atic review or meta-analysis was identified (i.e., Barr et al.
[7]). Our search of published clinical trials started begin-
ning with the end of the study period of the systematic
review by Barr et al. (May 1, 2006) and was conducted in
electronic databases (MEDLINE, Cochrane database,
ClinicalTrials.gov). In a third step, we performed a search
for observational studies (starting May 1, 2006).
The specific inclusion criteria for the systematic review
or meta-analysis were: 1) patients suffering from COPD; 2)
outcome: acute myocardial infarction (fatal or non-fatal);
3) exposure: B2A or MA; 4) control arm: active or placebo;
and 5) type of study: clinical trial or any kind of observa-
tional study (OS).Data extraction and quality assessment
All titles, abstracts, citations, and full texts included were
analysed by two independent reviewers who extracted the
data based on a standardized taxonomy. The taxonomy
covered the following 6 domains consisting of 42 items: i)
study identification characteristics (i.e., author, title,
reference, country of origin, publication year, source of
funding); ii) study characteristics (i.e., primary objective
and/or further objectives, setting); iii) participants’ char-
acteristics (i.e., age, gender, ethnicity, socio-economic
status, disease severity, duration of disease, co-
morbidities, co-treatments); iv) exposure (i.e., drug or
drug class studies, dosage, route of administration, dura-
tion of treatment, index date, time window of exposure,
description of comparator, indication of use); v) adverse
effects/outcome (i.e., definition of reported AE, method-
ology of AE monitoring, AE frequency, study design/number
of included studies for meta-analysis or systematic review,
inclusion criteria, exclusion criteria, time during the study
at which the AE is recorded, methodology of causality
assessment, total number of withdrawals/drop-outs,
reason for withdrawals/drop-outs, number of
withdrawals/drop-outs due to AE, number of participants
with AE by drug and indication, total number of AE); and vi)
key results (i.e., statistical techniques, length of follow-up,
number of participants included in the analysis, type ofanalysis, type of risk estimate, pooled risk estimates of AE
and 95% confidence interval (CI), sources and magnitude (I2)
of statistical heterogeneity).
The quality of each study included was assessed based
on a standardized questionnaire (developed under the su-
pervision of the co-author LI) containing 31 questions
applicable to randomized controlled trials, observational
studies, and systematic reviews (Appendix 2). The checklist
is divided into two parts reflecting a variety of issues:
definition and severity of AE, validity of study design, and
statistical methods (part 1); methods for AE identification,
reporting frequency in randomized controlled trials, and for
assessing causality in both OS and randomized controlled
trials (part 2). For each item contained in the questionnaire
one point was awarded by two independent reviewers (any
disagreement was resolved by consensus). The maximum
scores were determined for each study type as follows:
systematic reviews or meta-analysis 8 points, RCTs 17
points, cohort studies 12 points, and caseecontrol studies
10 points. For all study designs the following categories
were applied: “very good” (85% of maximum score),
“good” (<85%e70%), “satisfactory” (<70%e55%),
“inadequate” (<55%).
Statistical analysis
A meta-analysis was conducted for those drug classes the
sample sizes were most sufficient. Summarising the relative
risk (RR) estimates, a random effects model was applied.
The “metafor” package (version 1.6.0) of the statistical
software package R (version 2.14.1) was used for pooling
the logarithms of the single relative risks. Statistical het-
erogeneity for the group of studies was analysed using the I2
statistic. A p-value <0.05 was considered to indicate sta-
tistical significance. If sample size was insufficient for a
meta-analysis, the results of these studies were summa-
rized using a narrative synthesis.
Results
In total, eight relevant studies and systematic reviews
(Table 1) were identified in the literature search process:
two systematic reviews [7,8], two randomized controlled
trials [9,10], and four observational studies (including one
population-based cohort study, one cohort study, and two
nested caseecontrol studies) [5,11e13]. Three studies
compared tiotropium vs. placebo treatment [7e9], whereas
one study compared tiotropium vs. salmeterol [10]. In
contrast, the scope of observational studies was wider
covering tiotropium vs. non-tiotropium use [11], inhaled
beta-2 agonists (“no”, “any”, “new”, and “first use”) [5],
tiotropium vs. LABA [13], and new users of tiotropium vs.
new users of LABA monotherapy [12]. Risk estimates from
the selected studies for the comparison of tiotropium and
placebo (n Z 3) were pooled in a meta-analysis. The
remaining five studies were highly heterogeneous con-
cerning both the control arm and the study design. There-
fore, it was impossible to pool the results of these studies
based on a random effects model. Almost all studies (nZ 7)
focused on a combination of primary and secondary end-
points including various clinical and/or composed
Table 1 Summary of study characteristics.
First author Study design Number of studies/
number of centres/
database
Treatment Number of
patients
Age (years) Male (%) COPD severity
Barr [7] Systematic
review
4 trials Tiotropium vs. placebo,
or ipratropium
Tiotropium 1808;
ipratropium 179;
placebo 1281
Casaburi: tiotropium
65  9, placebo 65  9
Dusser: tiotropium
64.5  9.1, placebo
65.0  9.5
Brusasco: tiotropium
63.8  8.0, placebo
64.6  8.6
Vincken: tiotropium
63.6  8.2, ipratropium
64.5  8.1
Casaburi: tiotropium
66.5%, placebo 62.8%
Dusser: tiotropium
89%, placebo 87%
Brusasco:
tiotropium 77.4%,
placebo 76.3%
Vincken:
tiotropium 84%,
ipratropium 86%
Not reported
Celli [8] Systematic
review
30 trials Tiotropium vs. placebo Tiotropium 10,846;
placebo 8699
Tiotropium 65  9;
placebo 65  9
Tiotropium 76%,
placebo 76%
Tiotropium GOLD II:
26%, III: 49%, IV: 24%
placebo GOLD II: 25%,
III: 50%, IV: 24%
Tashkin [9] RCT 490 centres Tiotropium 18 mg
(HandiHaler) vs.
placebo
Tiotropium 2986;
placebo 3006
Tiotropium 64.5  8.4;
placebo 64.5  8.5
Tiotropium 75.4%,
placebo 73.9%
Tiotropium GOLD II:
46%, III: 44%, IV: 8%
placebo GOLD II: 45%,
III: 44%, IV: 9%
Vogelmeier
[10]
RCT 725 centres Tiotropium 18 mg
(HandiHaler) vs.
salmeterol 50 mg
Tiotropium 3707;
salmeterol 3669
Tiotropium 62.9  9.0;
salmeterol 62.8  9.0
Tiotropium 74.4%,
salmeterol 74.9%
Tiotropium GOLD II:
48%, III: 43%, IV: 9%
salmeterol GOLD II:
50%, III: 42%, IV: 8%
de Luise [11] Population-
based
cohort study
National health
services, residents
of North Jutland,
Aarhus and Viborg
counties in Denmark
Periods of tiotropium
use vs. periods of
non-tiotropium
use
Tiotropium 2870;
non-user 7733
40e59: tiotropium
n Z 700 (24.4%), non-
user n Z 2011 (26.0%)
60e74: tiotropium
n Z 1564 (54.5%), non-
user n Z 3431 (44.4%)
75þ: tiotropium n Z 606
(21.1%), non-user
n Z 2291 (29.6%)
Tiotropium 47.2%,
non-user 48.1%
Not reported
Suissa [5] Nested casee
control study
Saskatchewan Health
Services
SABA (no use vs. any use
vs. new use vs. first use)
Cases 1127;
controls 10,766
Cases 77  8.3,
controls 77  8.0
Cases 69%,
controls 55%
Not reported
Verhamme [13] Nested casee
control study
Integrated Primary
Care Information
project
Tiotropium vs. LABA Tiotropium 1048;
LABA 3214
40e59: tiotropium
n Z 225 (21.5%); LABA
n Z 863 (26.9%)
60e69: tiotropium
n Z 278 (26.5%); LABA
Tiotropium 61.0%,
LABA 56.9%
Tiotropium (GOLD
classification)
mild: 23%, moderate:
47%, severe: 29%,
very severe: 2%
(continued on next page)
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Table 1 (continued )
First author Study design Number of studies/
number of centres/
database
Treatment Number of
patients
Age (years) Male (%) COPD severity
n Z 828 (25.8%)
70þ: tiotropium n Z 545
(52.0%); LABA n Z 1523
(47.3%)
LABA
mild: 24%, moderate:
47%, severe: 27%,
very severe: 2%
Jara [12] Cohort study The Health
Improvement
Network (THIN)
New users of tiotropium
(HandiHaler) vs.
new users
of LABA monotherapy
Tiotropium 4767;
LABA 6073
40e49: tiotropium
n Z 149 (3%); LABA
n Z 362 (6%)
50e59: tiotropium
n Z 641 (13%); LABA
n Z 943 (16%)
60e69: tiotropium
n Z 1391 (29%); LABA
n Z 1730 (28%)
70e79: tiotropium
n Z 1759 (37%); LABA
n Z 1991 (33%)
80e89: tiotropium
n Z 769 (16%); LABA
n Z 976 (16%)
90þ: tiotropium n Z 58
(1%); LABA n Z 71 (1%)
Tiotropium 57%,
LABA 51%
Not reported
RCT: randomised controlled trial; SABA: short-acting beta-2-agonists; LABA: long-acting beta-2-agonists.
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Respiratory drug-related myocardial infarction 1081endpoints. The most frequent endpoints were as follows:
myocardial (adverse) events (n Z 7), all-cause mortality
(n Z 6), and COPD-related hospitalization (n Z 5). Two
studies compared health-related quality of life only (Table
2). In addition, the limitations of all included studies were
comparable and mostly associated with the known bound-
aries of systematic reviews and meta-analyses, e.g., dif-
ferences in study design or publication, selection and
reporting biases (Table 2).
Quality assessment
All studies were evaluated according to the standardized
questionnaire described above. Quality in both systematic
reviews was either assessed as “good” or “very good”, with
only minor shortcomings concerning the precise presenta-
tion of the criterion “severity of the adverse event”
(question 2) [7,8]. In general, the two randomized clinical
trials were of good quality, however, slight weaknesses
concerning the precision of ADE definition, details on ADE
severity description, and causality assessment existed
[9,10]. Quality of the two cohort studies [11,12] was
assessed as “good” to “very good” and “very good” for the
two nested caseecontrol studies [5,13]. To sum up, from a
methodological point of view, all studies have been
analyzed their endpoints accurately (Table 3).
Tiotropium overall
Sample size was large in all studies, with tiotropium pa-
tients ranging from 1048 to 10,846 cases. Age distribution in
all studies was similar starting at the age of 40 years (due to
the studies’ inclusion criteria), with a large proportion of
participants being older than 60 years. All studies had a
predominance of male patients (tiotropium 57e89% vs.
comparators 51e87%), except for the study by de Luise
et al. [11] which included more females (tiotropium 53% vs.
non-users 52%). Reporting of COPD severity (based on the
GOLD grading system [1]) was heterogeneous between all
studies: it remained totally unmentioned in four studies
[5,7,11,12]. In the study by Celli et al. patients with “se-
vere” and “very severe” COPD (stages III and IV) were
predominant [8], whereas “mild” to “severe” patients
(stages IeIII) were the largest group in the study by Ver-
hamme et al. [13]. Almost 90% of patients were “moderate”
(stage II) or “severe” (stage III) in the studies by Tashkin
et al. [9] and Vogelmeier et al. [10].
Tiotropium vs. placebo or periods of non-
tiotropium use
One publication by de Luise et al. [11] analysed the inci-
dence of MI during the use of tiotropium vs. periods of non-
tiotropium therapy resulting in an adjusted incidence rate
ratio of 1.05 (0.69e1.60, Table 3). The majority of studies
compared treatment with tiotropium vs. placebo resulting
in heterogeneous effects concerning the risk estimator: the
study by Barr et al. [7] reported a neutral effect (1.0
[0.2e3.9]), whereas Celli et al. [8] and Tashkin et al. [9]
revealed a lower risk of MI among tiotropium patients
(0.78 [0.59e1.02] and 0.71 [0.52e0.99], Table 3). Finally,we pooled the results of the three studies [7e9] for the
calculation of a pooled risk estimator. In total, 15,467 tio-
tropium patients suffered from 183 MI events, whereas in
the placebo-controlled arm 217 MI events were detected in
13,092 patients (Fig. 2). The calculated pooled relative risk
based on a random effects model was 0.74 (0.61e0.90)
indicating a reduction of MI in tiotropium patients
compared to placebo patients. There was no evidence of
statistical heterogeneity among the included trials
(I2 Z 0%; p Z 0.8090).
Tiotropium vs. active control arm
Comparing tiotropium with an active control arm, the
studies by Barr et al. [7] focussing on ipratropium (odds
ratio of 1.5 [0.2e15]) and Vogelmeier et al. [10] focussing
on salmeterol (incidence rate ratio/100 person years of
1.50 [0.74e3.02]) indicated an increased risk of MI in tio-
tropium users (Table 3). Two other relatively small studies
compared tiotropium against LABA use and found conflict-
ing evidence [12,13]. Verhamme et al. [13] calculated an
adjusted odds ratio of 0.67 (0.22e2.00), whereas, in
contrast, the study by Jara et al. [12] resulted in an
adjusted hazard ratio (aHR) of 1.26 (0.72e2.21, Table 3).
However, there was heterogeneity in study specifications
(e.g., exposure definition and confounding variables) and
results were non-significant with wide confidence intervals.
Short-acting inhaled beta-2 agonists
Finally, the study by Suissa et al. [5] compared a variety of
combinations associated with the treatment of short-acting
beta-2 agonists. In summary, every kind of usage (any
(current), new, or first time use) resulted in minor, non-
significant increases of the rate ratios (range 1.06e1.12,
Table 3) compared to non-usage.
Discussion
The aim of our study was to contribute on the evidence of
MI associated with the utilization of B2A or MA in COPD
patients. To sum up the eight studies of the literature re-
view, an MI-protective effect of tiotropium could be found
in studies comparing tiotropium vs. placebo. This beneficial
effect has been attributed to an effective COPD treatment
leading to a reduced number of cardiovascular events due
to e.g. a decreased rate of COPD exacerbations [14e17]. On
the other hand, in studies comparing tiotropium with active
control (e.g., salmeterol, ipratropium) assuming an effec-
tive treatment in both treatment arms, an increased MI risk
for patients treated with tiotropium was detected in some
studies. Observational studies revealed an increased risk in
the initial period after tiotropium or short-acting B2A was
ingested for the first time (Table 3). All studies were
assessed as having at least ”good” quality. However,
shortcomings in ADE-specific criteria, particularly ADE
definition, severity classification, and causality assessment
were revealed.
In our meta-analysis, we confirmed an earlier reported
[7e9] decrease of MI risk in patients receiving tiotropium
vs. placebo (0.74 [0.61e0.90]) based on the random effects
Table 2 Endpoints, duration and study limitations.
First author Endpoints Duration Limitations
Barr [7] PE: COPD exacerbations and related
hospitalisations, all-cause mortality
SE: disease specific mortality, health-
related QoL (SGRQ), symptom scores
(TDI), multidimensional measure of
breathlessness, FEV1 change and
forced FVC (from baseline and from
steady state 8e15 days after
randomization), adverse events (i.e.,
dry mouth, constipation, urinary
infection and obstruction, chest pain,
MI, arrhythmias, congestive heart
failure)
RCTs between 12 weeks and 12
months
Double counting of patients
randomised to tiotropium or of
patients from overlapping
publications, publication and
reporting biases, selection bias
(differential inclusion of
available trials), selective
reporting of secondary
endpoints and of non-intention
-to- treat reports in
publications
Celli [8] PE: all-cause mortality, selected CV
events (composite CV endpoint
encompassing CV deaths, nonfatal MI,
nonfatal stroke, sudden death,
sudden cardiac death, and cardiac
death)
RCTs between 4 weeks and 4
years
Integration of placebo-
controlled trials with active
controlled trials, differential
discontinuation, differences in
exposure, selection bias (most
evidence based on Health Lung
Study), incomplete AE
reporting of included studies,
higher premature
discontinuation in controls
compared with tiotropium
group;
meta-analysis limitations:
differences in populations,
study design, duration of trials,
collection of data, and
adjustment for differences in
exposure, susceptibility for
different diagnostic reportings
Tashkin [9] PE: annual rate of decline in mean
FEV1 before and after use of a study
drug and short-acting bronchodilators
in the morning (prebronchodilator)
and after the use of a study drug
(postbronchodilator) beginning on
day 30
SE: rate of decline in the mean FVC
and SVC, health-related QoL (SGRQ),
COPD exacerbations and related
hospitalizations, mortality from any
cause and from lower conditions
4-year RCT All respiratory therapies
(exceptional other inhaled
anticholinergic agents) allowed
by study design, very low
proportion of smokers at
baseline (30%)
Vogelmeier [10] PE: time to first COPD exacerbation
(defined as “an increase in or new
onset of more than one symptom of
COPD (cough, sputum, wheezing,
dyspnea, or chest tightness), with at
least one symptom lasting 3 days or
more and leading the patient’s
attending physician to initiate treat-
ment with systemic glucocorticoids,
antibiotics, or both (criterion for
moderate exacerbation) or to hospi-
talize the patient (criterion for se-
vere exacerbation)”)
1-year RCT (2 weeks run in, 12
months study period, 30 days
follow-up SAEs)
n/r
(continued on next page)
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Table 2 (continued )
First author Endpoints Duration Limitations
SE:
time to following first event:
 COPD exacerbation leading to
hospitalization
 moderate COPD exacerbation
 premature discontinuation of trial
medication
 COPD exacerbation or time to
discontinuation of study medication
because of worsening of underlying
disease
 COPD exacerbation treated with
systemic steroids
 COPD exacerbation treated with
antibiotics
 COPD exacerbation treated with
systemic steroids and antibiotics
number of patients with events
(occurrence):
 at least 1 COPD exacerbation
 at least 1 COPD exacerbation lead-
ing to hospitalization
 premature discontinuation of trial
medication
number of events:
 COPD exacerbations
 COPD exacerbations leading to
hospitalization
 moderate COPD exacerbations
 COPD exacerbations treated with
systemic steroids and/or antibiotics
pre-dose morning peak expiratory
flow rate measured by patients at
home during first 4 months of ran-
domized treatment
safety endpoints:
 serious AE
 AE leading to treatment
discontinuation
 treatment-related AE
 major adverse cardiovascular
events during treatment (fatal CV
disorders, sudden (cardiac) death,
cardiac death, serious AE (fatal and
non-fatal) from MI, stroke)
 all-cause mortality with onset of
fatal AE during treatment with
study medication þ 30 days
all-cause mortality including follow-
up of vital status from patients who
prematurely discontinued treatment
and date of death within 360 days
de Luise [11] Hospitalization for any reason,
hospitalization with cardiac discharge
diagnoses (atrial fibrillation or atrial
flutter, supraventricular tachycardia,
angina, MI, congestive heart failure,
Hospitalized patients from
January 1, 1977 to December
31, 2003 (Aarhus and Viborg)
and from January 1, 1980 to
December 31, 2003 (North
Misclassification of COPD and
MI discharge diagnoses in
medical record databases,
missing random treatment
assignment as therapy was
(continued on next page)
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Table 2 (continued )
First author Endpoints Duration Limitations
ventricular arrhythmia),
hospitalization for COPD
mortality endpoints: death from any
cause or due to sudden death, cardiac
arrest, MI, heart failure or other
cardiac cause, non-cancer respiratory
death
Jutland) determined by physicians (who
may prescribe certain
medications based on risk
factors for endpoints under
study) and not by investigators
using random assignment
Suissa [5] Acute MI Subjects who had been
dispensed at least three
bronchodilator prescriptions
within a 1-year period between
January 1, 1980 and December
31, 1997; follow-up until the
date of death, emigration from
the province, end of health
insurance plan coverage or
December 31, 1999
Precise indications whether
drugs were prescribed are
unavailable (study cohort was
formed from administrative
databases)
Verhamme [13] CV and cerebrovascular endpoints,
mortality
One-year pre-enrollment
period for patient
characterization followed by a
study period started in January
2000 and ended in May 2007
Confounders: COPD severity,
misclassification of the
outcome, investigation of
tiotropium HandiHaler (dry
powder inhaler) only due to
national restricted launch
policies of other manufacturers
(tiotropium Respimat (softmist
inhaler))
Jara [12] CV AE (aneurysm, atrial fibrillation,
cardiac arrest, coronary artery
disease, angina, MI, heart failure,
hypertension, stroke, syncope,
(ventricular) tachycardia),
respiratory AE (COPD exacerbation,
asthma exacerbation and pneumonia)
and other AE (constipation, dry
mouth, dysphagia, paralytic ileus/
bowel obstruction, renal failure,
tremor, urinary retention), all-cause
mortality
November 2002 (the earliest
use of tiotropium) until January
2007 (exposure to study
medication for duration of
prescribed therapy plus 30
days; patients were followed
from the date of their first
eligible prescription until the
earliest date of treatment end,
date of study end point, date of
transfer to a new practice,
death or January 2007)
Missing routine lung function
measures, composite endpoints
(all-cause mortality and all
strokes) potentially reduce
associations for cardiovascular
mortality and ischaemic stroke
differences in baseline risks
between treatment groups
(e.g., lung function results;
more LABA patients than
tiotropium patients exhibited
an asthma diagnosis
additionally to COPD diagnosis)
potential underreporting of
non-serious anticholinergic end
points (e.g., constipation,
urinary retention) resulting in
diluted RR estimates, missing
evaluation of dose response
(tiotropium HandiHaler)
AE: adverse event; CV: cardiovascular; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; MI: myocardial infarction; n/r:
not reported; QoL: quality of life; PE: primary endpoint; RCT: randomised controlled trial; RR: relative risk; SAE: serious adverse event;
SE: secondary endpoint; SGRQ: St George’s Respiratory Questionnaire; SVC: slow vital capacity; TDI: Transitional Dyspnea Index.
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Table 3 Risk estimators and quality assessment.
First author Type of risk estimate Comparator Estimator Quali score/
max. re)
Comments
Barr [7] Odds ratio (95% CI) Tiotropium vs. placebo Adjusted 1.0 (0.2e3.9) Very d (7/8) Only AE severity is not described
Tiotropium vs. ipratropium Adjusted 1.5 (0.2e15)
Celli [8] Incidence rate ratios
stratified by study
(Cochrane-Mantel-
Haenszel test)
Tiotropium vs. placebo Adjusted 0.78 (0.59e1.02) Good 8) e
Tashkin [9] Incidence rate ratio
per 100 person years
Tiotropium vs. placebo Adjusted 0.71 (0.52e0.99) Good /17) Shortcomings in AE definition,
causality assessment, and lack
of AE severity
Vogelmeier [10] Incidence rate ratio Tiotropium vs. salmeterol Adjusted 1.50 (0.74e3.02) Good /17) Shortcomings in AE definition,
causality assessment, and lack
of AE severity
de Luise [11] Incidence rate ratio Periods of tiotropium use
vs. periods of non
tiotropium use
Crude 0.97 (0.64e1.46)
adjusted 1.05 (0.69e1.60)
Very d (11/12) e
Suissa [5] Rate ratio SABA no use vs. any use Adjusted 1.06 (0.92e1.23) Very d (10/10) e
SABA no use e SABA any
current use*
Adjusted 1.12 (0.95e1.33)
SABA no use e SABA new
use**
Adjusted 1.12 (0.69e1.80)
SABA no use e SABA first
time use
Adjusted 1.02 (0.52e2.00)
Verhamme [13] Odds ratio Tiotropium vs. LABA Crude 0.76 (0.26e2.25)
adjusted 0.67 (0.22e2.00)
Very d (10/10) e
Jara [12] Hazard ratio Tiotropium vs. LABA Crude 1.26
adjusted 1.26 (0.72e2.21)
Good /12) Presentation of results could
have been improved
AE: adverse event; SABA: short-acting beta-2-agonists; LABA: long-acting beta-2-agonists; *Any current use: use of inhaled beta-2 onists in the 2 months before the index date, **New
use: current use of beta-2agonists with no other beta-2 agonist use of any form during the year before the index date.
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the included trials (I2 Z 0%; p Z 0.8090). From a phar-
macological perspective, this finding is to some extent un-
expected. By using MA leading to a decreased cholinergic
activity, an overweight in sympathetic activation leading to
an increased risk for MI seems reasonable. Nevertheless, an
increased risk of tiotropium might have been masked by an
efficacious COPD treatment leading to a decreased number
of COPD-related cardiovascular events. For quantifying the
exact cardiovascular substance-related CV risk, active
comparisons assuring a sufficient COPD treatment (e.g.
LABA) might be of outstanding importance. Nevertheless,
results will be also influenced by a LABA-containing control
arm due to LABA-related CV risks.
Endpoint “myocardial infarction“
Influence of all drugs in both classes (B2A and MA) on the
cardiovascular system is well-known [2,3]. Onset of these
symptoms is certainly followed by a dose reduction or
discontinuation of drug therapy, which may prevent from
more severe cardiac AEs (e.g., myocardial infarction)
resulting in a low number of these AEs. Currently, only a
few clinical studies dealing with MI (at least as secondary
endpoint) are available on this account as most in-
vestigators refer to it within the common term “side ef-
fects”. In contrast, pharmacoepidemiological database
studies more often contain specific analyses on MI as these
studies were conducted based on large datasets [4,5,18].
However, a combined endpoint is used in most studies only.
The study by Calverley et al. [19] summarized a mixture of
different specific symptoms within the general term “car-
diovascular event” (“coronary artery disorders“, “cardiac
arrhythmias”, “heart failures”, “cardiac disorder signs andsymptoms”, “myocardial disorders”, “cardiac valve disor-
ders”, “pericardial disorders”, “central nervous system
vascular disorders”, “arteriosclerosis”, “stenosis”,
“vascular insufficiency and necrosis”, “aneurysms and ar-
tery dissections”, and “embolism and thrombosis”). In this
context, Dong et al. [20] utilized a clinical endpoint called
“cardiovascular death”.
Comparison of endpoints in systematic reviews is
impeded by semantic heterogeneity and, hence, inter-
study comparability is limited (Table 2). Similar results
compared to ours concerning the MI endpoint were found in
studies containing combined endpoints. In a comprehensive
meta-analysis of 42 studies, Rodrigo et al. [21] found a
slightly lower risk for the combined endpoint “cardiovas-
cular event” for the treatment with tiotropium vs. placebo
(n Z 13 studies; risk ratio ManteleHaenszel: 0.91; 95% CI
[0.77e1.07]), but a significant higher risk for tiotropium vs.
the combination of salmeterol and fluticasone (n Z 2
studies; risk ratio ManteleHaenszel: 1.94, 95% CI
[1.06e3.55]). A study by Wedzicha et al. [22] verified these
results by reporting a higher rate of “cardiac events” in the
tiotropium treatment arm (5%) compared to patients
treated with salmeterol and fluticasone (3%).
A further problem concerning study comparability is the
uniform definition of the diagnosis “myocardial infarction”,
as a standardized definition is available since the year 2000
for the first time [23]. However, the problem remains that
most studies use different coding systems possibly influ-
encing the results. Particularly, coding systems in obser-
vational studies and secondary database studies differ
between single countries as International Statistical Clas-
sification of Diseases and Related Health Problems (ICD)
and International Classification of Primary Care (ICPC)
codes are used more often than Medical Dictionary for
Respiratory drug-related myocardial infarction 1087Regulatory Activities (MedDRA) classification terms nor-
mally used in clinical trials [5,8,13].
Background prevalence of myocardial infarction
COPD and MI are diseases occurring more often in elder
people as prevalence is sharply increasing for both diseases
starting from an age of 40 years [24,25]. In addition to age,
the existence of common risk factors (e.g., smoking and air
pollution) increases the risk for both COPD and MI [26e28].
Therefore, the assessment of causality between drug
therapy and onset of adverse event is very difficult, as
COPD patients without B2A or MA may also suffer from MI.
In this context, randomization enables a uniform distribu-
tion of both known and unknown risk factors in clinical
trials; hence, detected effects can be assigned more pre-
cisely to a particular drug therapy. However, strict inclusion
and exclusion criteria lower the number of patients eligible
for these studies. For example, a frequent inclusion crite-
rion in almost all studies dealing with B2A and MA in COPD
patients was being a current smoker or ex-smoker with at
least  10 pack-years smoking history, which is limiting the
generalization of results significantly. Controlling for con-
founders is difficult in non-randomized studies, as these
confounders cannot adequately be considered due to a high
number of concomitant diseases and co-medication influ-
encing the risk for cardiac adverse events in COPD patients
[29,30]. That is the reason why comparability of observa-
tional studies is strongly limited, as every study presents a
different selection of confounders [12,13].
Heterogeneity of control arms
Another problem emerging in all study types is the large
number of drug therapy combinations available for COPD
treatment [31]. GOLD guidelines recommend LABA or LAMA
in treatment step 2 [1], but even drugs of one class differ in
important pharmacological aspects (e.g., onset time of
bronchodilator effects is much shorter when using for-
moterol instead of salmeterol (both LABA)) [32]. However,
these differences may influence MI risk and a combination
of active ingredients for a pooled evaluation or meta-
analysis is inappropriate. Therefore, a large number of
subgroup analyses is shown in systematic reviews [20].
Comparison of results for long-acting (LAMA, LABA)
versus short-acting substances (SAMA, SABA) is difficult for
several reasons. Whereas LAMA and LABA are used on a
regular basis as controller medication, SAMA and SABA are
used as reliever medication on an “as needed basis”
resulting in different exposures [1]. For treatment step 1
(mild COPD), only short-acting agents are recommended,
whereas for patients with a more severe COPD (steps 2e4) a
combined usage of long-acting and short-acting compounds
is recommended [1] resulting in patient groups with
different baseline characteristics. In general, a similar
distribution of co-medication is essential for assessing the
risk of an adverse event for a specific drug. Nevertheless,
particularly in observational studies, but also in randomised
controlled trials, there might be differences in co-
medication utilization. For example, in patients receiving
placebo, a more frequent usage of reliever drugs cannot beexcluded and should be considered as a confounder in all
studies.
Many patients are treated with a combination of B2A or
MA and inhaled ICS. Drug combinations are frequently
available as one inhaler (e.g., fixed combination of for-
moterol and budesonide). ICS influence the inflammatory
processes of both the lung and coronary artery diseases
and, therefore, a protective cardiac effect of ICS in terms
of reducing inflammatory processes influencing coronary
artery disease cannot be excluded [33,34]. In most studies
ICS is one of the permitted co-medications and, therefore,
a possible protective cardiac effect of ICS could bias the
results. In contrast, use of OCS is associated with an
increased risk for AMI in COPD patients [35,36]. Since OCS
are used for treating acute exacerbations, increased AMI
risk might primarily reflect a higher probability of cardiac
events in these vulnerable patients instead of a causal
relationship for OCS usage. Hence, adjusting for ICS and
OCS co-medication is highly important. However, observa-
tional studies often consider ICS as fixed combination
therapies only [13], as it cannot be verified whether both
substances are ingested simultaneously or consecutively.
In general, when analyzing secondary data it is difficult
to assess whether the reliever drug was taken before the
onset of the MI resulting in a difficult causality assessment
for a particular respiratory drug. Periods of LABA/LAMA
usage vs. periods without treatment are compared in the
majority of observational studies based on secondary data.
For this reason, users are categorized in “current users”,
“new users”, and “past users”, even though a uniform
definition of these terms does not exist. For example, Jara
et al. [12] defined “new users” as “patients [who] had to
have at least two years of baseline data with no use of a
long-acting inhaler prior to their first prescription for tio-
tropium or LABA”, whereas Suissa et al. [5] considered
patients who “had not received beta-2-agonists of any form
during the 3e12 months before the index date”.Different risks for dosage and application forms
The majority of drugs for the treatment of COPD or asthma
are used via inhalation. These drugs have been launched in
a variety of devices (e.g., metered-dose inhaler with or
without a spacer, dry powder inhaler or soft mist inhaler)
differing in which way (passively or actively generated) the
medication is dispensed [37]. For example for tiotropium, a
soft mist inhaler device (Respimat) was developed due to
irritant effects and insufficient drug application in patients
with breathing difficulties using the dry powder application
(HandiHaler). Since the Respimat aerosol contains a higher
fraction of fine particles which is applied more slowly
compared to the HandiHaler, a higher drug deposition in
the lungs is reached. Accordingly, there is a lower recom-
mended daily dose for Respimat compared to HandiHaler
(5 mg versus 18 mg). Taking into account the somewhat
conflicting pharmacokinetic data not excluding a higher
systemic exposure of tiotropium Respimat 5 mg compared to
tiotropium HandiHaler 18 mg [38e40] and a potential su-
periority of Respimat compared to HandiHaler regarding
COPD exacerbations as suggested by cross-study compari-
sons [9,41], safety concerns regarding well-known dose-
1088 M. Rottenkolber et al.dependent antimuscarinic effects (e.g. cardiac arrhyth-
mias) could be of clinical relevance.
Supporting these considerations, intake of tiotropium
Respimat was found to be associated with an increased risk
for safety issues in several studies. Singh et al. [42] found a
dose-dependent all-cause mortality risk in patients
receiving tiotropium Respimat compared to placebo (5 mg:
RR Z 1.46 [95%CI: 1.01e2.10] 10 mg: RR Z 2.15 [95%CI:
1.05e4.51]). Supporting the dose-dependency of cardiac
side effects, Verhamme et al. showed that patients
suffering from a chronic kidney disease stage 3e5 were at
increased mortality risk (aHRZ 1.52 [95%CI: 1.02e2.28]) if
they have received tiotropium, a compound partially
excreted by the kidneys [43]. In a recently published meta-
analysis, Dong et al. [20] found that the tiotropium Respi-
mat was associated with an universally increased risk of
overall death compared with tiotropium HandiHaler (OR
1.65; 95% CI 1.13e2.43). The risk was more evident for
cardiovascular death, in patients with severe COPD and at
higher daily dosages.
For evaluating the risk of death and major cardiovascular
events of tiotropium Respimat versus HandiHaler in a direct
comparison, a randomized, double-blind, parallel group trial
(TIOSPIR) was conducted [44] in 17,135 COPD patients
treated either with a once-daily dose of tiotropium Respimat
(2.5 or 5 mg) or tiotropium HandiHaler (18 mg). To sum up,
cardiovascular mortality was similar across the three treat-
ment groups (2.1%, 2.0%, and 1.8% for Respimat 2.5 mg,
Respimat 5 mg, and HandiHaler, respectively). Concerning
major adverse CV events, no statistical significant differ-
ences (3.9%, 3.9%, and 3.6%) were found even though slightly
fewer MI were reported in HandiHaler than Respimat group
[44]. Nevertheless, subsequent analyses showed an
increased risk for fatal and non-fatal MIwhen combining both
Respimat groups compared to HandiHaler (RR 1.37; 95% CI
1.00e1.85; pZ 0.05) [45] leading to a critical discussion of
the cardiac safety of the Respimat device in particular in
patients suffering from cardiac comorbidities [3].
A concomitant intake of beta-2-agonists and tiotropium
is a further issue worth mentioning. For example in the
TIOSPIR trial, 62% were taking long-acting beta-2-agonists
in addition to tiotropium. From a pharmacological point of
view, these patients might have an increased risk for car-
diac adverse events due to a concomitant sympathetic
activation (by beta-2-agonists) and antimuscarinic effects
(by tiotropium). Nevertheless, there are only a few safety
data focusing on a combined therapy including tiotropium
and long-acting beta-2-agonists showing no clear evidence
for an increased risk of adverse events [46e48]. In partic-
ular data for patients suffering from cardiac or renal
comorbidities are lacking. For these patients whom might
be at increased risk for cardiac events, further research is
needed to allow a more reliable “real-life” benefit-risk-
assessment of tiotropium.Conclusion
To sum up, the evidence obtained from published meta-
analyses, clinical trials, and observational studies provides
no clear evidence for an increased MI risk in patients
receiving short-acting B2A or tiotropium versus activecontrol arm. By pooling all available studies for the com-
parison between tiotropium versus placebo, a previously
reported protective effect of tiotropium regarding
myocardial infarctions was supported in our meta-analysis.
However, since a profound validation of MI events is lacking
and device-related MI risk differences might not be
excluded, additional device-specific studies with myocar-
dial infarction as primary endpoint are required before a
final conclusion can be drawn particularly for tiotropium.
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